Pharvaris (PHVS) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.70
- EPS estimate
- −$0.76
- EPS surprise
- +7.17%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 12, 2025
Pharvaris reported Q3 2025 results on November 12, 2025. The company posted a loss of $0.70 per share, narrower than the $0.76 loss analysts expected, a 7.17% beat. A year earlier, in Q3 2024, the loss was $0.86 per share. The table shows no revenue for Pharvaris and no revenue estimates in any quarter.
Every quarter in the table is a loss. Quarterly losses have mostly ranged between about $0.55 and $1.00 per share, with the widest at $1.24 in Q4 2022 and the narrowest at $0.40 in Q2 2022. Full-year losses were $2.78 per share in 2023 and $2.67 in 2024. The first three quarters of 2025 add up to a loss of $2.60, compared with $2.01 for the same period of 2024. The record has gaps: Q4 2021 and Q3 2022 are missing. Against estimates the results are evenly split, with seven beats, eight misses and one match across the 16 quarters shown.
Pharvaris has reported fourth-quarter results in early April and second-quarter results in August, but the table holds no report after November 2025. The next figures added will show whether losses per share stay near the 2024 and 2025 range.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 12, 2025 | −$0.76 | −$0.70 | +7.17% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.90 | −$0.98 | −8.30% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.83 | −$0.92 | −10.65% | $0.00 | SEC |
| Q4 2024 | Apr 7, 2025 | −$0.75 | −$0.66 | +11.54% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.66 | −$0.86 | −30.05% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | −$0.59 | −$0.59 | +0.32% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.61 | −$0.56 | +7.65% | $0.00 | SEC |
| Q4 2023 | Apr 10, 2024 | −$0.59 | −$0.82 | −38.82% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.64 | −$0.61 | +3.93% | $0.00 | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.67 | −$0.69 | −3.03% | $0.00 | SEC |
| Q1 2023 | May 8, 2023 | −$0.80 | −$0.66 | +17.89% | $0.00 | SEC |
| Q4 2022 | Apr 5, 2023 | −$0.70 | −$1.24 | −77.87% | $0.00 | SEC |
| Q2 2022 | Sep 12, 2022 | −$0.59 | −$0.40 | +32.97% | $0.00 | — |
| Q1 2022 | May 11, 2022 | −$0.52 | −$0.53 | −1.59% | $0.00 | — |
| Q3 2021 | Nov 10, 2021 | −$0.56 | −$0.45 | +19.59% | $0.00 | — |
| Q2 2021 | Jul 30, 2021 | −$0.52 | −$1.11 | −114.86% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Pharvaris (PHVS) last report earnings?
Pharvaris last reported on Nov 12, 2025, covering fiscal Q3 2025.
Did PHVS beat earnings estimates?
Yes. Pharvaris reported EPS of −$0.70 for Q3 2025 against a −$0.76 estimate — a 7.17% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.